2min

OpenAI launched purpose-built pharma AI models targeting drug discovery, going head-to-head with Google's established healthcare play.

Vertical AI models are eating horizontal APIs — pharma pays premium.

Anthropic shipped Claude Opus 4.7 — a 'less risky' model than their Mythos system that spooked regulators last week.

Safety theater or real capability throttling? Either way, constraints shape your builds.

Factory AI just raised at $1.5B valuation for enterprise coding — making Cursor's consumer play look quaint.

Enterprise AI coding tools command 10x consumer valuations for good reason.

Data center delays are choking AI expansion — physical infrastructure is the new bottleneck, not compute power.

Power and permits matter more than parameters now. Proximity premium incoming.

Charles Schwab launching direct bitcoin and ether trading to compete with Robinhood — boomer brokerage gloves are off.

Traditional finance legitimacy accelerates. Your normie friends can finally buy crypto.

Bitcoin-gold portfolio study shows higher returns without extra risk — the barbell strategy gets academic validation.

Institutional allocation models now have cover. Expect more treasury diversification.

UK finalizes crypto regulation timeline — trading and custody rules drop October 2027, giving clear runway.

Two-year regulatory clarity window. Time to build compliant before walls close.

Elon's X Money could disrupt PayPal but crypto features face regulatory hurdles — payments yes, DeFi maybe not.

X's 500M users make it instant fintech scale. Regulatory capture determines feature set.

Stock markets hitting records despite Iran war as traders bet on contained conflict and diplomatic progress.

Risk-on sentiment means volatility traders getting squeezed. Fade the fear premium.

China's export data from Canton Fair shows economy vulnerable to prolonged Iran conflict disrupting trade routes.

Supply chain reshuffling creates arbitrage opportunities. Short China exposure, long alternatives.